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The objective of this study was to test a new version of the
Magnetic Resonance Disease Severity Scale (MRDSS2),
incorporating cerebral gray matter (GM) and spinal cord
involvement from 3T MRI, in modeling the relationship
between MRI and physical disability or cognitive status in
multiple sclerosis (MS). Fifty-five MS patients and 30
normal controls underwent high-resolution 3T MRI. The
patients had an Expanded Disability Status Scale score of
1.6±1.7 (mean±SD). The cerebral normalized GM fraction
(GMF), the T2 lesion volume (T2LV), and the ratio of T1
hypointense LV to T2LV (T1/T2) were derived from brain
images. Upper cervical spinal cord area (UCCA) was
obtained from spinal cord images. A within-subject d-score
(difference of MS from normal control) for each MRI
component was calculated, equally weighted, and summed
to form MRDSS2. With regard to the relationship between
physical disability and MRDSS2 or its individual
components, MRI–Expanded Disability Status Scale
correlations were significant for MRDSS2 (r=0.33,
P=0.013) and UCCA (r=−0.33, P=0.015), but not for GMF
(P=0.198), T2LV (P=0.707), and T1/T2 (P=0.240). The
inclusion of UCCA appeared to drive this MRI–disability
relationship in MRDSS2. With regard to cognition, MRDSS2
showed a larger effect size (P=0.035) than its individual
components [GMF (P=0.081), T2LV (P=0. 179), T1/T2
(P=0.043), and UCCA (P=0.818)] in comparing cognitively
impaired with cognitively preserved patients (defined by the
Minimal Assessment of Cognitive Function in MS). Both
cerebral lesions (T1/T2) and atrophy (GMF) appeared to
drive this relationship. We describe a new version of the
MRDSS, which has been expanded to include cerebral GM
and spinal cord involvement. MRDSS2 has concurrent
validity with clinical status. NeuroReport 25:1156–1161
© 2014 Wolters Kluwer Health | Lippincott Williams &
Wilkins.
NeuroReport 2014, 25:1156–1161
Keywords: brain, cognition, MRI, multiple sclerosis, physical disability,
spinal cord
aDepartment of Neurology,
bDepartment of Radiology,
cLaboratory for
Neuroimaging Research, Brigham and Women’s Hospital and
dPartners Multiple
Sclerosis Center, Harvard Medical School, Boston, Massachusetts, USA
Correspondence to Rohit Bakshi, MD, MA, Laboratory for Neuroimaging
Research, One Brookline Place, Brookline, Suite 602, MA 02445, USA
Tel: +1 617 525 6550; e-mail: rbakshi@bwh.harvard.edu
Received 20 June 2014 accepted 14 July 2014
Introduction
Conventional MRI-based brain lesion and atrophy mea-
sures have contributed to the understanding of multiple
sclerosis (MS) pathophysiology. However, these mea-
sures show weak correlations with clinical status, as
measured by the Expanded Disability Status Scale
(EDSS), and have an unreliable strength for predicting
clinical change. Composite MRI measurements offer an
emerging approach to assess the full range of MS-related
structural changes [1–4].
We previously described a composite scale to define the
severity of damage in MS, known as the Magnetic
Resonance Disease Severity Scale (MRDSS); this
original version (MRDSS1) combined three cerebral
measures: (i) T2 hyperintense lesion volume (LV), (ii)
the ratio of T1 (hypointense) to T2 LVs (T1/T2), and (iii)
normalized whole brain volume (a surrogate of whole
brain atrophy). This initial version of the MRDSS
showed high effect sizes in comparing MS clinical phe-
notype groups, was associated with clinical severity
measures, and was highly sensitive to longitudinal
change when monitoring patients for 3 years [3,4].
Notable limitations are that our previous studies evaluating
MRDSS used low-resolution 1.5T MRI scanning plat-
forms and did not consider cerebral gray matter (GM) or
spinal cord damage, both of which are now recognized in
numerous studies as key contributors to impairment in
patients with MS [5–13]. The goals of this study were (i) to
further develop and refine the MRDSS using (a) a 3T
MRI platform with a high-resolution scan protocol and (b)
advanced MRI measures – cerebral GM atrophy and spinal
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volume (GMV)+T2LV+T1/T2+upper cervical spinal
cord area (UCCA)] and (ii) to compare the association of
MRDSS1, MRDSS2, and individual MRI measures with
neurologic and cognitive functions. This is the first study to
consider GM and spinal cord damage in an MS composite
scale. We have presented these data in the preliminary
form at the 2014 meeting of the American Academy of
Neurology, Philadelphia.
Methods
Participants
Table 1 summarizes the demographic and clinical char-
acteristics of the participants. The sample included 55
consecutive patients with MS who met the following
criteria: (i) age between 18 and 55 years; (ii) MS diagnosis
of either relapsing–remitting, secondary progressive, pri-
mary progressive, or clinically isolated demyelinating
syndrome [14]; (iii) absence of other major medical,
neurologic, or neuropsychiatric disorders; (iv) lack of any
relapse or corticosteroid use in the 4 weeks before MRI or
start of disease-modifying therapy 6 months before MRI
(to reduce confounding effects on MRI); and (v) no his-
tory of smoking or substance abuse. Forty-three patients
(78%) were receiving disease-modifying treatment at the
time of MRI. Within 3 months of MRI, each patient
underwent examination by an MS specialist neurologist,
including EDSS scoring. All patients also underwent a
formal neuropsychological evaluation by a PhD in clinical
psychology (B.I.G.) and a research fellow under her
supervision (A.A.). We also included normal controls (NC;
n=30), recruited as previously detailed [15], with an age
and sex distribution comparable to that in the MS group
(Table 1). All participants gave their informed consent for
this Institutional Review Board-approved study.
Cognitive evaluation
Neuropsychological performance was assessed by the
Minimal Assessment of Cognitive Function in MS
(MACFIMS) battery [16]. The study participants had not
been previously exposed to any components of this test
battery. Patients also completed the Center for
Epidemiologic Studies Depression scale to control for
depressive symptoms in the analysis of MRI–cognition
relationships. Given the small number of participants in
the NC group, demographically adjusted T-scores were
calculated for the patients with MS using regression-
based norms, with impairment on a MACFIMS compo-
nent defined as a T-score of 35 or less [17]. Cognitive
impairment was defined as impairment on two or more
MACFIMS components [16], allowing subcategorization
of the MS group as either cognitively impaired (n=20) or
cognitively preserved (n=35).
MRI acquisition
Participants underwent a consistent scan acquisition
protocol on the same MRI platform (3T Signa; General
Electric, Milwaukee, Wisconsin, USA), using the same
head or spinal coil. The head was imaged in all partici-
pants, and the cervical spinal cord was imaged in all
except seven NCs, with the following pulse sequences
[18–20]:
(1) Brain: coronal three-dimensional modified driven-
equilibrium Fourier transform (MDEFT): TR=7.9 ms,
TE=3.14ms, flip angle=15°, slice thickness=1.6 mm,
pixel size=0.938×0.938mm.
(2) Brain: axial T2-weighted fast fluid-attenuated
inversion-recovery (FLAIR): TR=9000 ms, TE=
151ms, TI=2250 ms, slice thickness=2m m(n og ap ) ,
pixel size=0.976×0.976mm.
(3) Spine: axial fast spin-echo T2-weighted images:
TR=6117 ms, TE=110 ms, slice thickness=3mm
(no gap), pixel size=0.937×0.937 mm.
Image analysis
Brain and spinal cord MRI analysis was carried out in the
Laboratory for Neuroimaging Research using Jim (v. 5;
Xinapse Systems, Northants, UK, http://www.xinapse.com)
and statistical parametric mapping (SPM8; Wellcome
Department of Cognitive Neurology, London, UK, http://
www.fil.ion.ucl.ac.uk/spm) operating in Matlab (version
2009a; The MathWorks Inc., Natick, Massachusetts,
USA). MRI analysts were unaware of clinical information.
Our techniques are semi-automated, and we have
established their operational procedures and high reli-
ability [12,18,20–23].
Compartment-specific brain volume segmentation
Our pipeline, on the basis of our earlier work [21–23], has
been detailed recently [12]. Briefly, an expert first per-
formed manual removal of the skull, paranasal sinuses, and
soft tissue overlying the brain to isolate the intracranial
volume (ICV=brain parenchymal tissue+subarachnoid
space). Images were then aligned with a common template,
bias-field corrected, normalized, and segmented into GM,
white matter (WM), and cerebrospinal fluid maps in SPM8.
Mutually exclusive masks for each tissue were derived from
probability maps. WM volume (WMV), GMV, and brain
Table 1 Demographic and clinical data
Multiple sclerosis Normal controls
Number (n)5 5 3 0
Age (years) (mean±SD) 41.1±9.0 43.9±6.3
Men [n (%)] 17 (31) 9 (30)
Disease category [n (%)]
Clinically isolated syndrome 4 (7) –
Relapsing–remitting 46 (84) –
Secondary progressive 4 (7) –
Primary progressive 1 (2) –
Disease duration (years) (mean±SD) 8.3±7.4 –
EDSS score (mean±SD) 1.6±1.7 –
Receiving disease-modifying therapy (%) 78% –
EDSS, Expanded Disease Status Scale.
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after manual correction of misclassification of MS lesions and
underestimation of the deep GM contour. Normalized
compartment-specific global volumes were then obtained as
follows: WM fraction (WMF=WMV/ICV), GM fraction
(GMF=GMV/ICV), and total brain parenchymal fraction
[BPF=(WMV+GMV)/ICV].
Lesion segmentation
Brain FLAIR hyperintense and MDEFT hypointense
lesions were expert-segmented using a semi-automated
edge-finding tool based on local thresholding in Jim5 to
obtain whole brain T2 (FLAIR) hyperintense and T1
(MDEFT) hypointense LVs (T2LV, T1LV), as descri-
bed previously [18,20]. To assess the destructive poten-
tial of lesions, the ratio of T1LV to T2LV (T1/T2) was
calculated for each participant.
Spinal cord segmentation
A rapid semi-automatic segmentation tool in Jim5 was
implemented using the highly reliable and validated
active surface method [10] to segment the contour of the
spinal cord from the T2-images. The total UCCA, from
the top of C2 to the base of C5, was derived for each
participant, using consistent landmarks [10].
Creation of MRDSS2
To derive MRDSS2, a d-score (difference from NCs) for
each MRI component was calculated for all MS patients,
as follows:
dGMF ¼
GMFMS GMFmeanNC ðÞ
GMFSDMS
:
The d-scores were equally weighted and summed for
each patient to form a composite of the four variables as
follows:
dMRDSS2 ¼
dlogT2LV dGMF   dUCCAþdlogitðT1=T2Þ

4
:
A composite score using the three original components
(used in the previous original version) of MRDSS1 was
also calculated for comparison with MRDSS2, as follows:
dMRDSS1 ¼
dlogT2LV dBPFþdlogit T1=T2 ðÞ

3
:
Thus, two versions of the MRDSS were tested. The
second version differed from the first version in two ways:
(i) substitution of GMF for BPF; (ii) the addition of spinal
cord data. Further, because of the restricted range of the
current MS sample, we relied on d-scores (rather than
z-scores, which were used in the original version).
Table 2 shows the results of all d-scores and MRDSS
calculations; Table 3 shows the raw MRI data in the MS
and NC groups.
Statistical analysis
The MS and NC groups were compared on all MRI
measures using Wilcoxon’s rank sum tests. Associations
between MRI-derived data and measures of clinical status
were assessed using Spearman’s correlation coefficient in
the MS group. Cognitively impaired and cognitively pre-
served MS groups were compared using two-sample t-tests.
In addition to the unadjusted comparison, the association
between MRI measures and cognitive impairment was
investigated, adjusting for depression (Center for
Epidemiologic Studies Depression scale scores) using lin-
ear regression. A P-value less than 0.05 was considered
significant, and a P-value less than 0.10 was considered a
trend to significance in this exploratory study. Effect size
(d) was also calculated for group comparisons [24].
Results
MRI–disability correlation in the MS group
As shown in Table 4, with regard to all available MRI
measures of brain and spinal cord involvement, as well as
the two MRDSS versions, we tested their relationship with
physical disability (EDSS score). With respect to the
individual MRI components that compose the two
MRDSS versions, only BPF and UCCA showed significant
Table 2 d-Scores for MRI components in the multiple sclerosis
group (n=55)
MRI variable(s) Mean±SD (range)
dBPF –0.49±1( −4.18 to 1.20)
dGMF –0.32±1( −3.26 to 1.56)
dUCCA 0.04±1( −2.10 to 1.90)
dlogT2LV 4.12±1( 2 . 4 4 –6.14)
dlogitT1T2 0.19±1( −1.98 to 2.19)
dMRDSS1 (T2LV, T1/T2, BPF) 1.60±0.74 (0.42–4.02)
dMRDSS2 (T2LV, T1/T2, GMF, UCCA) 1.15±0.54 (0.15–2.72)
d-Scores were calculated by comparing patients with normal controls (see the
Methods section).
BPF, brain parenchymal fraction; GMF, gray matter fraction; MRDSS1, previous
version (version 1) of the Magnetic Resonance Disease Severity Scale; MRDSS2,
expanded new version of the Magnetic Resonance Disease Severity Scale; T1LV,
total brain T1 (modified driven-equilibrium Fourier transform) hypointense lesion
volume; T2LV, total brain T2 (fluid-attenuated inversion-recovery) hyperintense
lesion volume; T1/T2, T1LV/T2LV in each participant; UCCA, upper cervical
cord area.
Table 3 MRI comparisons between patients and controls
Multiple sclerosis
(n=55)
Normal controls
(n=30) P-value
T2LV (ml) 13.6 (11.7) 0.4 (0.6) <0.0001*
T1LV (ml) 6.1 (7.3) 0.2 (0.3) <0.0001*
T1/T2 0.409 (0.203) 0.291 (0.267) 0.034*
BPF 0.831 (0.031) 0.846 (0.017) 0.035*
GMF 0.520 (0.029) 0.529 (0.021) 0.14
UCCA
(mm
2)
2302.3 (350.1) 2288.2 (322.8) 0.78
Values are expressed as mean (SD).
BPF, brain parenchymal fraction; GMF, gray matter fraction; T1LV, total brain T1
(modified driven-equilibrium Fourier transform) hypointense lesion volume; T2LV,
total brain T2 (fluid-attenuated inversion-recovery) hyperintense lesion volume; T1/
T2, T1LV/T2LV in each participant; UCCA, upper cervical cord area.
P-values are based on Wilcoxon’s rank sum tests; *P<0.05.
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two MRDSS versions, MRDSS1 (T2LV, T1/T2, BPF)
showed a trend toward a significant correlation with EDSS
score (P<0.10). In contrast, MRDSS2 (T2LV, T1/T2,
GMF, UCCA) showed a significant correlation with EDSS
score (P<0.05), with the lowest P-value among all MRI
measures; the correlation was only weak-to-moderate in
strength. Thus, the addition of GMF and UCCA measures
to MRDSS2 appears to improve the validity of the scale
from the perspective of overall neurologic disability in
patients with MS. Specifically, inclusion of UCCA appeared
to be driving this MRI–disability relationship in MRDSS2.
MRI–cognition relationships
As shown in Table 5, with regard to the comparison of
MRI measures between cognitively impaired and cog-
nitively preserved patients with MS, we considered the
individual components on their own, as well as the two
composite scales. With respect to the individual MRI
components that composed the two MRDSS versions,
only T1/T2 and BPF showed significantly increased
severity in the cognitively impaired group (P<0.05);
GMF showed a trend toward significance (P<0.10), and
the moderate effect size for this difference approached
the level seen for T1/T2 and BPF. Considering the two
MRDSS versions, both MRDSS1 (T2LV, T1/T2, BPF)
and MRDSS2 (T2LV, T1/T2, GMF, UCCA) showed
significantly higher severity in the cognitively impaired
group (both P’s<0.05), with moderate-to-strong effect
sizes (d 0.66–0.74). Although the effect size was higher
for MRDSS1, the P-values for both were in the significant
range and of similar strengths. Thus, the addition of GMF
and UCCA measures to MRDSS2 did not limit the
validity of the scale from the perspective of cognitive
impairment in patients with MS. Moreover, one notes the
value of creating a composite score in that the largest
effect sizes for the comparison of the two cognition groups
were achieved with the two MRDSS versions versus the
individual MRI components. Finally, in considering the
relevance of each core component’s contribution to
MRDSS2, both cerebral lesions (T1/T2) and cerebral
atrophy (GMF) parameters appeared to be driving the
relationship between MRDSS2 and cognition.
Discussion
We describe an expanded new version of the MRDSS
(MRDSS2) to assess the severity of disease in patients
with MS. This version encompasses a wide range of
MRI-defined measures of pathologic involvement,
including brain atrophy, brain lesions, and spinal cord
atrophy. The scale also considers the destructive poten-
tial of lesions by including the ratio of each patient’s total
T2 lesion burden that shows corresponding hypointen-
sity on T1-weighted images. The expanded version
incorporates cerebral GM atrophy and spinal cord atrophy
for the first time. In addition, the MRI was performed at
3T to bring to bear the higher-resolution imaging offered
on this emerging platform compared with lower-field
(e.g. 1.5 T) platforms. The present study shows that
MRDSS2 has concurrent validity with physical disability
and cognitive function in patients with MS, on the basis
of the fact that we showed significant MRI–clinical
relationships in a cross-sectional analysis.
Given the moderate effect size of the GMF difference
between cognitively impaired and cognitively preserved
patients, the inclusion of cerebral GMV in MRDSS2 is
warranted. Brain atrophy is common and begins to
Table 4 Relationship between MRI and overall neurologic disability
in the multiple sclerosis group (n=55)
Expanded disability status scale
MRI variable(s) Spearman’s rP -value
T2LV 0.05 0.707
T1/T2 0.16 0.240
BPF –0.29 0.030*
GMF –0.18 0.198
UCCA –0.33 0.015*
MRDSS1 (T2LV, T1/T2, BPF) 0.25 0.067
MRDSS2 (T2LV, T1/T2, GMF, UCCA) 0.33 0.013*
BPF, brain parenchymal fraction; GMF, gray matter fraction; MRDSS1, previous
version of the Magnetic Resonance Disease Severity Scale; MRDSS2, expanded
(new) version of the Magnetic Resonance Disease Severity Scale; T1LV, total
brain T1 (modified driven-equilibrium Fourier transform) hypointense lesion
volume; T2LV, total brain T2 (fluid-attenuated inversion-recovery) hyperintense
lesion volume; T1/T2, T1LV/T2LV in each participant; UCCA, upper cervical
cord area.
*P<0.05.
Table 5 Comparison of MRI and cognition in the multiple sclerosis group
MRI variable(s) Cognitively impaired (n=20) Cognitively preserved (n=35) Unadjusted P-value Adjusted P-value Effect size (d)
dT2LV 4.37 (1.08) 3.97 (0.93) 0.171 0.179 0.40
dT1/T2 0.57 (1.07) –0.02 (0.90) 0.043* 0.044* 0.60
dBPF –0.90 (1.17) –0.25 (0.82) 0.038* 0.029* –0.64
dGMF –0.65 (1.09) –0.13 (0.91) 0.081 0.092 –0.52
dUCCA 0.08 (0.97) 0.02 (1.03) 0.818 0.826 0.06
MRDSS1 (T2LV, T1/T2, BPF) 1.95 (0.89) 1.40 (0.57) 0.019* 0.011* 0.74
MRDSS2 (T2LV, T1/T2, GMF, UCCA) 1.38 (0.66) 1.02 (0.41) 0.035* 0.022* 0.66
Values are presented as mean (SD).
BPF, brain parenchymal fraction; GMF, gray matter fraction; MRDSS1, previous version (version 1) of the Magnetic Resonance Disease Severity Scale; MRDSS2,
expanded new version of the Magnetic Resonance Disease Severity Scale; T1LV, total brain T1 (modified driven-equilibrium Fourier transform) hypointense lesion volume;
T2LV, total brain T2 (fluid-attenuated inversion-recovery) hyperintense lesion volume; T1/T2, T1LV/T2LV in each participant; UCCA, upper cervical cord area.
*P<0.05; unadjusted P-values are based on two-sample t-tests; depression (Center for Epidemiologic Studies Depression scale)-adjusted P-values are based on linear regression.
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[6]. Whole brain atrophy is dominated by GMV rather
than WMV loss [6,8,11,21]. Moreover, the level of global
GM atrophy closely tracks MS clinical disease stage/
phenotype [8] and has a high degree of relevance in
predicting both physical disability [21] and cognitive
impairment [22]. One proposed benefit of focusing on
GM rather than WM atrophy is that the GM is likely less
prone than the WM to transient fluctuations in volume
(e.g. fluid and cellular shifts) [6]. However, univariate
comparisons in the present study indicate that BPF has a
higher validity than GMF for all comparisons. This might
be related to the improved reliability in measuring BPF
versus GMF because of the more common segmentation
misclassifications and variability associated with mea-
surement of the latter [5,18].
A major strength of this study is the inclusion of spinal
cord involvement in MRDSS2. Previous MS MRI com-
posite scale versions from our group and other groups
have not included spinal cord metrics [1–4]. Yet, a
growing body of evidence indicates that spinal cord
atrophy is common and highly relevant to disability in
advanced stages of MS [9,10,12,13]. Further, spinal cord
involvement appears to occur somewhat independently
from brain involvement [12], supporting the notion that
combining brain and spinal cord MRI metrics provides
complementary information on overall disease severity.
The inclusion of spinal cord volume in MRDSS2 likely
improved the validity of the scale, owing to the strength
of its univariate relationship with physical disability
(EDSS score).
MRDSS2 takes advantage of the availability and refine-
ment of 3T MRI, which is growing in use for MS routine
clinical care and research evaluations. Our previous work
has shown the higher sensitivity to brain lesions and
increased relevance toward the prediction of cognitive
impairment derived from 3T versus 1.5 T MRI in MS
[20]. This advantage, coupled with the ability to derive
higher-resolution images with tolerable scan times, drove
our decision to switch the scale to a 3T platform.
However, in the present study, we did not directly
compare 1.5 T-derived with 3T-derived MRDSS scores.
Several additional aspects of our study are worthy of
comment. Our MS sample was dominated by mildly
affected, treated patients with relapsing forms of the
disease. Given that only 9% of our patients had pro-
gressive forms of MS, further studies are required to
assess the role of this scale in advanced forms of the
disease. Because our sample had a restricted range of
disease severity, there was limited power to detect dis-
ease involvement on each MRI parameter. For example,
we did not find significant spinal cord or GM atrophy in
the patients relative to controls. Our future studies will
test whether methods of normalization of the spinal cord
volume [7] and assessment of diffuse pathology in the
normal-appearing WM [2] and cortical lesions improve
the scale. We will also test nonequal weighting of the
MRI measures to improve the validity of the scale. In
addition, the T1 hypointense lesions in the present study
were defined on gradient-echo rather than spin-echo
images; the latter are a more established tool to evalu-
ate destructive lesions [3]. Finally, this cross-sectional
study provides the opportunity to determine whether the
MRDSS2 predicts the rate of longitudinal clinical dete-
rioration or whether it effectively tracks the response to
disease-modifying therapy [25].
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